Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 151 to 160 of 279 total matches.

Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
, adrenocortical insufficiency, posterior reversible encephalopathy syndrome, hypoglycemia, musculoskeletal pain ...
Akeega (Janssen), a fixed-dose combination of the oral poly(ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula) and the antiandrogen abiraterone acetate (Zytiga, and others), has been approved by the FDA for use in combination with prednisone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Niraparib has been available since 2017 for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Abiraterone acetate has been available since 2011 for treatment of CRPC...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e146-7   doi:10.58347/tml.2023.1684c |  Show IntroductionHide Introduction

Shockwave Therapy for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
, but pain, erythema, ecchymoses, and hematuria can occur with low-intensity shockwave therapy. Serious ...
Low-intensity extracorporeal shockwave therapy similar to that used to fragment kidney stones or gallstones is a new option for treatment of erectile dysfunction that is now being advertised extensively in the US. It has not been approved by the FDA for treatment of erectile dysfunction.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):190-1   doi:10.58347/tml.2023.1690d |  Show IntroductionHide Introduction

Eroxon — An OTC Gel for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
cause headache, flushing, and back pain, and they have been associated with sudden losses of vision ...
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel (Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved OTC and topical treatment for erectile dysfunction. It is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2   doi:10.58347/tml.2024.1715c |  Show IntroductionHide Introduction

A Three-Antigen Hepatitis B Vaccine (PreHevbrio)

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
and was superior to Engerix-B in those ≥45 years old. Adverse Effects: Injection-site pain and tenderness ...
The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has been available in Israel since 2000.
Med Lett Drugs Ther. 2022 May 16;64(1650):73-5 |  Show IntroductionHide Introduction

Two New Oral Testosterone Products for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
formulations can raise serum concentrations into the normal range, but injection-site pain, transference ...
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury caused by tumors, trauma, or radiation. Jatenzo, another oral testosterone undecanoate formulation, was approved for the same indication in 2019. No testosterone products are approved for treatment of low testosterone levels due solely to...
Med Lett Drugs Ther. 2022 Oct 31;64(1662):172-4 |  Show IntroductionHide Introduction

Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
reported in ≥5% of patients on dialysis included hypertension, abdominal pain, dizziness, hypersensitivity ...
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months. It is the first HIF-PHI and the first oral drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7   doi:10.58347/tml.2024.1696a |  Show IntroductionHide Introduction

Rozanolixizumab (Rystiggo) for Myasthenia Gravis

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
, diarrhea, pyrexia, nausea, injection-site reactions, abdominal pain, and arthralgia can occur. Dosage ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. It is the first drug to be approved for treatment of generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart Hytrulo) and the complement inhibitors eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31   doi:10.58347/tml.2024.1696c |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, and abdominal pain are most common Pancreatitis, hepatotoxicity, pericarditis, pneumonitis, and a lupus-like ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
. Other symptoms include dyspepsia, chest pain, belching, and chronic cough. Endoscopy is recommended to evaluate ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
irritation, esophagitis, abdominal pain, diarrhea, and other GI adverse effects. Acute-phase reactions (low ...
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12   doi:10.58347/tml.2024.1706a |  Show IntroductionHide Introduction